2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving

2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving

In recent years, a Valeant Pharmaceuticals (NYSE: VRX) quarterly earnings report was grounds to call out sick from work, bury yourself under the blankets, and pray you'd still have money left when the day was complete. However, things changed during the previous quarter.

Back in August, the embattled drugmaker wound up reporting organic growth from both of its core operating segments, Bausch & Lomb and Salix Pharmaceuticals, and it stuck by its full-year EBITDA forecast of $3.6 billion to $3.75 billion. While far from anything worth crowing over, it wasn't a bad report. That's the first time investors could say such a thing in about two years.

Image source: Getty Images.

Continue reading

Source: Fool.com